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ABSTRACT 
Predicting antidepressant treatment response has been a clinical challenge for major depressive disorder 
(MDD). The inflammation hypothesis of depression suggests that cytokines play a key role in the 
pathophysiology of MDD and alterations in peripheral cytokine levels are associated with antidepressant 
treatment outcome. Present meta-analysis aimed to examine the association between baseline peripheral 
cytokine levels and the response to antidepressant treatment and to evaluate whether changes of cytokine 
levels were associated with the response to antidepressant treatment in patients with MDD. Human-based 
studies published in any language in peer-reviewed journals were systematically searched from the 
PubMed, Embase and Web of Science databases, from inception up to October 2018. The search terms 
included cytokine, depressive disorder and antidepressant and their synonyms. Case-control or case-case 
studies reporting on levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, CRP, TNF-α, IFN-γ, GM-
CSF, MIP-1α and Eotaxin-1 in patients with MDD based on validated depression scales both before and 
after antidepressant treatment were included. Of 7408 identified records, 44 studies met inclusion. 
Standardized mean differences in each cytokine were evaluated and random-effects meta-analyses were 
performed. MDD patients who responded to antidepressant treatment had lower baseline IL-8 levels than 
the non-responders (Hedge’s g = -0.28; 95% CI, -0.43 to -0.13; P = 0.0003; FDR = 0.004). Antidepressant 
treatment significantly decreased levels of TNF-α (Hedge’s g = 0.60; 95% CI, 0.26 to 0.94; P = 0.0006; 
FDR = 0.004) only in responders and responders showed significantly more decreased TNF-α levels 
compared to non-responders (P = 0.046). These findings suggested that alterations in peripheral cytokine 
levels were associated with antidepressant treatment outcomes in MDD. Further investigations are 
warranted to elucidate sources of heterogeneity and examine the potentiality of using inflammatory 
cytokines as novel predictive markers for the pharmacological treatment of MDD.    
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Introduction 
Major depressive disorder (MDD) is the most prevalent psychiatric disorder with an estimated life-time 
prevalence of 10-20% 
1
. Second-generation antidepressants, e.g. selective serotonin reuptake inhibitors 
(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), are the most commonly used 
pharmacological treatments for MDD, however only ~30% of the patients achieve remission with the first 
prescribed antidepressant 2. A challenge in treating MDD is the heterogeneity among patient response. 
The monoaminergic theory has been the dominant hypothesis of MDD, and most antidepressants are 
considered to primarily modulate monoaminergic neurotransmission. However, emerging evidence has 
suggested that aberrant inflammatory processes are involved in the development of MDD and also in 
mediating the response to antidepressant treatment 3, 4. Cytokines are key messengers between immune 
cells, mediating the initiation and cascade of inflammatory response and can have both pro- and anti-
inflammatory properties 4, 5. The cytokine hypothesis of depression posits that cytokines play a key role in 
the pathophysiology of MDD 4, 5. Much attention has been devoted to the study of interleukin-1β (IL-1β), 
IL-6 and tumor necrosis factor α (TNF-α), which have been found to be elevated in serum/plasma and 
cerebrospinal fluid of depressed patients in the absence of comorbid somatic diseases 6. Anti-
inflammatory cytokines, such as IL-4 and IL-10, were shown to have lower levels in depressed 
individuals 7, 8. Antidepressant treatments also influence inflammatory processes, specifically reduction of 
peripheral IL-6, IL-10, TNF-α and the monocyte chemoattractant protein 1 (MCP1) were reported in 
MDD patients after antidepressant treatment in recent meta-analyses 9. However, by evaluating the MDD 
patients as a whole group, those studies cannot differentiate the reduction in cytokine levels between 
patients who are antidepressant responders and non-responders. Studies have suggested that decrease in 
certain cytokine levels, e.g. TNF-α, were seen only in SSRI responders 10, 11. Interestingly, baseline 
cytokine levels have been reported to be involved in the response to antidepressant treatment. For 
example, higher levels of IL-6 were associated with treatment refractory depression 11. 
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The association between MDD and disturbed peripheral cytokine levels has been examined in various 
meta-analyses 6, 12, however very few meta-analyses have evaluated the association between baseline 
cytokine levels and treatment response. Strawbridge et al conducted the first such meta-analysis, however 
due to the limited number of studies available at that time, only three cytokines (IL-6, TNF-α and CRP) 
were subject to small meta-analyses from which no clear picture emerged 13. These reported effects 
should be interpreted with caution because of possible publication bias. With emerging studies 
investigating the effect of inflammatory cytokine levels on antidepressant treatment, it is important to 
perform an updated, methodologically rigorous meta-analysis on the association between peripheral 
cytokine levels and response to antidepressant treatment in MDD.  
Materials and Methods 
Inclusion criteria 
Records were screened regarding the following inclusionary criteria: 1) adult patients suffering from any 
depressive disorder (i.e., MDD, persistent depressive disorder) diagnosed according to the international 
diagnosis tools, e.g. Diagnostic and Statistical Manual of Mental Disorders (DSM), or the International 
Classification of Diseases (ICD); 2) any kind of pre-treatment assessment of inflammatory 
cytokine/chemokine, including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, CRP, TNF-α, IFN-γ, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), MIP-1α (a.k.a CCL3) or Eotaxin-1 (a.k.a. 
CCL11); 3) treatment including at least 4 weeks of continuous administration of any antidepressant; 4) 
standardized post-treatment symptom measure with a reported cut-off value dividing patients into non-
responders and responders. Exclusive criteria include: 1) Studies conducted in bipolar patients, unless 
separate data for unipolar patients could be extracted; 2) Studies which included a psychological or 
physiological stressor, or anti-inflammatory treatment either by a targeted agent or by specific 
immunomodulatory drugs (e.g. non-steroidal anti-inflammatory drugs were excluded, but not 
psychotropic medications). 
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Search strategy 
A systematic search was conducted in the PubMed, Embase, and Web of Science databases from 
inception up to October 2018 (JJL and YBW). Key words and subject headings were combined in 
accordance with the thesaurus of each database. The search string consisted of three components all of 
which were required: 1) “cytokine” and synonyms, including its components (e.g., IL-1); 2) “depressive 
disorder” and synonyms; and 3) “antidepressant” and synonyms. All the included studies were conducted 
in humans and written in English. The details of the strategy are available in the Supplementary Table 1. 
Data extraction  
We extracted the means, standard deviation (SD) and sample sizes for both responders and non-
responders in addition to methodological and participant characteristics. In studies that provided log-
transformed values, the raw scale was transformed based on Higgins et al’s method one 14. In studies that 
provided comparison results between responders and non-responders, or before and after treatments, 
measures of z-score, t-score and P-values were extracted. If the data were missing from the original study, 
we contacted the corresponding authors. Data was also extracted from bar chart using Engauge Digitizer 
when the authors could not provide the original data 15.  
Quality assessment of included studies 
We referred to the New-castle-Ottawa scale for observational studies 16, together with Cochrane common 
classification scheme for bias, and adapted a quality tool containing following parameters to assess the 
methodological quality of included studies: 1) Was the sample size ≥ 40 at baseline (Yes = 1, No = 0); 2) 
Whether the severity of depression were reported at baseline (Yes = 1, No = 0); 3) Whether potential 
confounders were assessed for both responders and non-responders (age, gender, smoking, body mass 
index, and time of blood draw) (for each confounder: Yes = 1, No = 0; the maximum of this parameter is 
5); 4) Whether the patients were drug-naïve or experienced a washout period (Yes = 1, No = 0); 5) 
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Whether the attrition rate ≤ 20% (Yes = 1, No = 0); 6) Whether we used data approximation or data 
extraction software (Yes = 0, No = 1); 7) Whether the manufacturer or parameters of the test were 
reported (Yes = 1, No = 0). Accordingly, the total score may vary from 0 to 11, with a higher score 
indicating a higher research quality. 
Statistical analysis 
Meta-analyses were conducted only when each cytokine was investigated with at least three individual 
datasets. Standardized mean difference and 95% CI were estimated for each cytokine, providing an 
unbiased effect size (ES) 17. Heterogeneity across studies was assessed using the Cochran Q test and was 
quantified with the I2 statistic 18. I2 < 25% was deemed to have low heterogeneity, 25% to 75%, medium 
heterogeneity and I2 ≥ 75% high heterogeneity. We anticipated a high degree of heterogeneity therefore 
pooled ES using a random-effects model. An ES of 0.2 was considered low, 0.5 moderate, and 0.8 large 19. 
Sensitivity analyses were performed for statistically significant ES estimates by excluding one study from 
analyses at a time to verify whether a single study turned results non-significant or otherwise changed the 
direction of the ES. Publication bias was inspected using funnel plot for asymmetry and examined using 
Egger’s test. A P-value < 0.05 was considered the presence of small-study effect 20. The trim-and-fill test 
was used to estimate the ES adjusting for publication bias 21. To further investigate sources of 
heterogeneity across studies, subgroup or random-effects meta-regression analyses were conducted. The 
potential confounders were considered: sex (%), age, sample type (serum/plasma), medication status on 
study-entry, length of treatment, cytokine detection methods (ELISA or other), study quality, publication 
year, the source of the patients (inpatient/outpatient/mixed). All analyses were performed using R 22 
metafor package 23. P value ≤ 0.05 was considered statistically significant. 
Results 
Characteristics of included studies 
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In total, 7408 potentially eligible studies were identified, of which 44 original studies met the inclusion 
criteria and were included in our meta-analysis (Figure 1, Supplementary Table 2). All studies were in 
longitudinal design, measuring the inflammatory cytokines pre- and post-treatment. Most studies 
dichotomized patients into responders and non-responders at the end of the study based on a ≥ 50% 
reduction of the score from the selected depression severity rating scale. Eight studies considered all 
patients to be responders 8, 24-30. Forty-two studies were able to provide data of response to exclusively 
pharmacological treatment and two studies provided the cytokine values by combining both 
pharmacological and non-pharmacological treatments 24, 31. Three studies pre-selected treatment-resistant 
patients to study the effect of augmentation treatments 32-34. 
Baseline inflammatory cytokine levels and its association with antidepressant treatment response 
IL-8 levels were investigated in nine studies comprising 397 responders and 311 non-responders. MDD 
patients who showed better treatment response at the endpoint had significantly lower baseline IL-8 levels 
compared to the non-responders, with a moderate ES (Hedge’s g = -0.28, P = 0.0003, FDR = 0.004, 
Table 1, Figure 2a, 32, 33, 35-41). Neither small-study effect (Egger’s test for publication bias: P = 0.20) nor 
heterogeneity was observed (Q = 3.44, P = 0.90; I2 = 0). In sensitivity analysis, the exclusion of any single 
study one-at-a-time did not alter the direction or statistical significance of the ES.  
CRP levels were numerically lower in those who subsequently became responders, though the difference 
between responders and non-responders was not statistically significant (Hedge’s g = -0.13, P = 0.07, 
Table 1, Figure 2b, 11, 31, 34, 37, 38, 42-48). No small-study effect was observed (Egger’s test: P = 0.87) and the 
heterogeneity was small (Q = 20.47, P = 0.04; I2 = 15.59). Subgroup analyses showed that studies 
recruiting inpatient subjects were associated with lower heterogeneity compared to studies with outpatient 
patient source (Supplementary Table 3).  
Baseline IL-6 levels did not significantly differ between responders (n = 565) and non-responders (n = 
561) across 19 included studies (Hedge’s g = -0.91, P = 0.36, Figure 2c, 10, 11, 31, 33-38, 41, 42, 49-57). No small-
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study effects were observed (Egger’s test: P = 0.10). The ES remained insignificant after adjustment for 
publication bias. The heterogeneity was large (I2 = 97.49%). Subgroup analyses suggested that using 
ELISA-based detection method, plasma sample type and inpatient subject source were associated with 
higher heterogeneity between studies, compared to other types of assay (e.g. multiplex beads array or 
flow cytometry etc), serum sample type and outpatient/mixed patient source, respectively 
(Supplementary Table 3). Meta-regression did not identify any significant study-specific covariate that 
could explain the heterogeneity (Supplementary Table 4).   
No differences of baseline IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12 TNF-α, IFN-γ, GM-CSF, MIP-1α and 
Eotaxin-1 levels were found between patients who were subsequent responders and non-responders (all P > 
0.05). The forest plots for these estimates were provided in Supplementary Figure 1-11. The 
comparisons of log-scale transformed data were provided in Supplementary Table 5.  
Effects of treatment and outcome of treatment response 
Levels of TNF-α were significantly decreased after antidepressant treatment only in responders with a 
moderate ES (Hedge’s g = 0.60, P = 0.0006, FDR = 0.004, Table 2, Figure 3a, 8, 10, 11, 24-26, 32, 33, 35-42, 44, 46, 
49, 50, 52, 56, 58-63) but not in non-responders (Hedge’s g = 0.14, P = 0.18, Supplementary Figure 12). In 
responders, there was evidence of small-study effects (Egger’s test: P = 0.03). The ES did not change 
after adjustment for publication bias. The heterogeneity in the responder group was large (Q = 221.78, P 
< 0.001; I2 = 90.98%). Subgroup analyses suggested that the measurement of TNF-α with ELISA method 
was associated with higher heterogeneity compared to other types of assay (Supplementary Table 6). 
Meta-regression analysis showed that the reduction of TNF-α levels in responders was significantly 
negatively correlated with ELISA based methods (Supplementary Table 7). Sensitivity analysis showed 
that the exclusion of any single study one-at-a-time did not alter the direction or statistical significance of 
the ES. We also compared the changes of TNF-α levels (ΔTNF-α = endpoint - baseline) between 
responders and non-responders and found that after antidepressant treatment responders had significantly 
more decreased TNF-α levels compared to non-responders (P = 0.046). 
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Levels of IL-5 were significantly reduced after antidepressant treatment only in responders with a 
moderate ES (Hedge’s g = 0.67, P < 0.0001, FDR = 0.0014, Table 2, Figure 3b, 36, 37, 44) but only 
nominally significant in non-responders (Hedge’s g = 0.65, P = 0.04, FDR = 0.56, Supplementary 
Figure 13). There was no evidence of publication bias in both groups but the heterogeneity was large in 
non-responders (Q = 6.34, P = 0.04, I2 = 80.71%). Sensitivity analysis showed that the exclusion of any 
single study one-at-a-time did not alter the direction or statistical significance of the ES in responders. No 
significant difference in changes of IL-5 (ΔIL-5) levels were found between responders and non-
responders. 
Levels of GM-CSF were significantly decreased after antidepressant treatment only in responders with a 
moderate ES (Hedge’s g = 0.33, P = 0.007, FDR = 0.03, Table 2, Figure 3c, 33, 36, 44) but not in non-
responders (Hedge’s g = 0.16, P = 0.47, Supplementary Figure 14). In the responders, there was no 
evidence of publication bias (Egger’s test: P = 0.75) or significant heterogeneity (Q = 3.86, P = 0.28, I2 = 
3.58%). Sensitivity analysis showed that the exclusion of two of the three studies one-at-a-time changed 
the statistical significance of the ES. No significant difference in changes of GM-CSF (ΔGM-CSF) levels 
were found between responders and non-responders. 
No significant treatment effects were observed on levels of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, 
IFN-γ, CRP, MIP-1α, and Eotaxin-1 in either responders or non-responders (all P > 0.05, Supplementary 
Figure 15-36). The log scaled data comparison was provided in Supplementary Table 8. 
Discussion 
This meta-analysis investigated the relationship between peripheral cytokines levels and response to 
antidepressants treatment in depression. Our results suggested that MDD patients who showed better 
response to antidepressant treatment had lower baseline IL-8 levels compared to the non-responders, 
while antidepressant treatment significantly decreased TNF-α, IL-5 and GM-CSF levels only in 
responders.  
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Our meta-analysis for the first-time suggested IL-8 was associated with antidepressant treatment response 
in MDD. IL-8 is a well-documented chemotactic factor for the recruitment of neutrophils to the sites of 
infection and damage 64. Later it was shown to activate neutrophil function and may serve as a secondary 
mediator of inflammation. In peripheral tissues, IL-8 can be secreted by monocytes, lymphocytes and 
endothelia, and can infiltrate neutrophils through the blood-brain barrier 64-66. In the central nervous 
system (CNS), activated microglia is the main secretory source of IL-8 and expresses CXCR2 receptor for 
the chemokine, providing a positive feedback mechanism for a sustained amplification of inflammatory 
response 67. However, the detailed functions of IL-8 are still not clear. IL-8 may play both pro- or anti- 
inflammatory roles depending on the concentration, which may in part explain the inconsistent 
association between IL-8 levels and depression. For example, high circulating levels of IL-8 have been 
shown to decrease the infiltration of neutrophils to the inflammatory site 68. A recent study reported 
higher baseline IL-8 levels predict poor antidepressant response in bipolar disorder 69, suggesting 
antidepressant response may share common mechanisms between MDD and bipolar depression. We 
should mention that we can not exclude the possibility that the association between a lower baseline IL-8 
level and better antidepressant treatment outcome is due to the improvement in patients’ depressive 
symptoms over time, since very few studies have examined the levels of inflammatory cytokines in a 
control group both at baseline and endpoint. 
Compared to Strawbridge et al’s study, more cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, 
MIP-1α, Eotaxin-1 and IFNγ) were included in our study which complemented the results of previous 
study. Kohler and colleagues 70 performed currently the most comprehensive meta-analysis in the field 
and it is one of the landmark studies investigating peripheral alterations in cytokine and chemokine levels 
after antidepressant treatment in major depressive disorder. Based on Kohler et al’s study, we 
complemented the evaluation of the association between levels of baseline cytokine and response to 
antidepressant treatment and we hypothesized that responders and non-responders may change differently 
in cytokine levels in response to the treatment. Therefore, the search strategy was different between the 
 11 
two studies resulting in different studies included in the analysis. The primary focus of Kohler et al’s 
study was to investigate the changes of cytokine levels before and after antidepressant treatment in all 
depression patients while we focused on the changes in responders and non-responders separately. 
Several cytokines, including TNF-α and IL-10, were reported in their study to be decreased after 
antidepressant treatment, however the results should be cautiously interpreted because the changes may 
only be a reflection from the responders. The maintenance of heightened cytokine levels, e.g. TNF-α, 
possibly underscores a lack of clinical improvement from the non-responders. Consistently, we found 
levels of TNF-α were decreased only in responders and responders had significantly more decreased 
TNF-α levels (ΔTNF-α) compared to non-responders. Although antidepressants may decrease TNF-α 
levels, we should note that both our study and previous meta-analyses have found a high degree of 
heterogeneity across studies, suggesting TNF-α levels may be sensitive to outside signals thus subject to 
dynamic changes 13, 70. Antidepressants have been shown to have anti-inflammatory effects both in 
peripheral immune cells and microglia in the CNS, the latter being the main cells responsible for 
inflammatory process in the brain  71-73. Peripheral cytokines can also exert effects on CNS by entering the 
brain through volume diffusion or via active cytokine transporters at the blood-brain barrier 67. 
The mechanism underlying antidepressant response is complicated and much of what is known came 
from pharmacogenetic studies. Interestingly, some genetic markers that survived genome-wide 
association significance were reported to locate in genes involved in inflammatory process. E.g. studies 
from GENDEP cohort reported markers in IL-11 gene and on a lower level of significance, IL-6 74, which 
support the role of inflammatory pathways in antidepressants efficacy. IL-5 gene is located on human 
chromosome 5, which is in close proximity to the genes encoding for GM-CSF, IL-3 and IL-4. We found 
antidepressant decreased IL-5 and GM-CSF levels only in responders, suggesting the responders may 
have different genetic background compared to the non-responders and that these two genes may be 
modulated by the same genetic loci in responders. We should note that the results of decreased IL-5 and 
GM-CSF levels in responders were generated from only 3 studies, providing limited power to draw a 
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definite conclusion. Besides, we did not find significant difference in changes of IL-5 (ΔIL-5) and GM-
CSF (ΔGM-CSF) levels between responders and non-responders. IL-10 is considered an anti-
inflammatory cytokine, however we found that it had a decreased trend after antidepressant treatment in 
responders. We speculate that both IL-5 and IL-10 belong to the T helper 2 (Th2)-derived cytokines, 
therefore may share common pathways that can be affected by antidepressant treatment. Similarly, 
previous reports have shown that long-term treatment with SSRIs increased Th1-derived cytokines (e.g. 
IL-1β, IL-2, and IFNγ) while decreased Th2-derived cytokines (IL-4, IL-5, IL-6 and IL-10) 75.  
There are several limitations in our study. We only searched three widely used database, nevertheless, the 
search strategy was carefully developed as all the relevant studies were identified and no study was added 
by manual search. Conference papers were included if data were available after we contacted with the 
authors. Future progress will be facilitated by the comprehensive concern of all the possible gray 
literature. Due to the small number of studies included in each analysis, we should mention that we could 
not exclude the possibility of publication bias and small study-effects even though Egger’s test has been 
performed. The methodological quality of included studies varied significantly. The quality assessment 
showed that many of the original studies were at moderate to high risk of bias. Eighteen in forty-four 
studies had a sample size lower than 40. We only dichotomized the patients into responders and non-
responders due to the difficulty to retrieve depressive severity data that measured as a continuous 
outcome, which may limit our statistical power in the analysis. Similarly, we were unable to get enough 
data to control variables such as smoking status and body mass index, which may affect cytokine levels. 
Future studies will benefit from the strict study design and increased sample size. There was substantial 
heterogeneity across studies, which may be only partially explained by meta-regression analyses, thus the 
results should be interpreted with caution. Although all studies included pharmacological treatment, the 
mechanisms of action varied between different drugs, limiting the conclusiveness of our findings. Two 
studies included non-pharmacological treatment which may present alternative mechanisms of cytokine 
action, thus weaken the associations we observed.  
 13 
Conclusion remark 
Our study is to date the most comprehensive meta-analysis investigating the association of levels of 
circulating cytokines and antidepressant treatment response. Although so many cytokines have been 
investigated by researchers, our meta-analysis demonstrated that most of the associations were not 
significant. Our results showed that MDD patients with lower baseline circulating IL-8 levels were 
associated with better response to antidepressant treatment, suggesting levels of IL-8 may be useful for 
identifying subjects that will fail to respond to current antidepressant therapies and for determining novel 
treatment strategy. The mechanisms of IL-8 in antidepressant response in CNS warrants further studies, 
e.g. induced pluripotent stem cell technology can be used as an in vitro model. In addition to measuring 
circulating IL-8 levels, genetic polymorphisms in IL-8 and genes interact with or involved in IL-8 
pathways are also potential candidates that can predict treatment response, which warrants future 
investigations. 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of study 
selection. 
Figure 2. MDD patients who showed better treatment response at the endpoint had significantly lower 
baseline 2a) IL-8 levels compared to the non-responders. Although 2b) CRP and 2c) IL-6 were 
numerically lower in the responders, the difference was not statically significant from non-responder 
patients. Each square shows the effect size for a single study, with the horizontal line running through 
each square demonstrating the width of the 95% CI. The size of the square is proportional to the weight 
attributed to each study. The diamond represents the summary effect size with the middle equaling the 
summary effect size and the width depicting the width of the overall 95% CI.  
Figure 3. Antidepressant treatment significantly decreased levels of 3a) TNF-α, 3b) IL-5, 3c) GM-CSF 
only in treatment responders, but not in non-responders. Each square shows the effect size for a single 
study, with the horizontal line running through each square demonstrating the width of the 95% CI. The 
size of the square is proportional to the weight attributed to each study. The diamond represents the 
summary effect size with the middle equaling the summary effect size and the width depicting the width 
of the overall 95% CI. 



Table 1. Primary meta-analyses of studies measuring baseline peripheral cytokines in antidepressant responders and non-responders. 
Cytokines Responders (N) Non-responders (N) ES (95% CI) P-value I2 (%) P-value Egger’s test 
IL-1β 227 239 -0.08 (-0.46, 0.30) 0.67 70.25 0.09 
IL-2 168 186 0.08 (-0.29, 0.45) 0.67 56.01 0.28 
IL-4 232 260 -0.15 (-0.34, 0.02) 0.09 0 0.30 
IL-5 163 143 -0.13 (-0.55, 0.29) 0.54 62.46 0.43 
IL-6 565 561 -0.91 (-1.15, 0.42) 0.36 97.49 0.10 
IL-8 397 311 -0.28 (-0.43, -0.13) 0.0003 0 0.20 
IL-10 237 283 -0.05 (-0.36, 0.27) 0.78 61.37 0.87 
IL-12 68 79 0.09 (-0.32, 0.50) 0.67 29.30 0.69 
TNF-α 738 517 -0.06 (-0.19, 0.06) 0.33 11.97 0.06 
IFNγ 223 221 -0.10 (-0.29, 0.09) 0.29 0 0.13 
GM-CSF 148 158 0.03 (-0.23, 0.29) 0.84 17.05 0.03 
CRP 518 454 -0.13 (-0.28, 0.01) 0.07 15.59 0.96 
MIP-1α 112 72 -0.16 (-0.75, 0.43) 0.59 71.76 0.60 
Eotaxin-1 128 79 -0.77 (-2.15, 0.61) 0.27 94.99 0.46 
 
Table 2. Primary meta-analyses of studies measuring peripheral cytokines in MDD patients before and after antidepressant treatment. 
Cytokines Responders  Non-responders 
N 
studies 
ES (95% CI) P-value I2 (%) P-value 
Egger’s test  
 N 
studies 
ES (95% CI) P-value I2 (%) P-value 
Egger’s test  
TNF-α 28 0.60 (0.26, 0.94) 0.0006 90.98 0.03  24 0.14 (-0.07, 0.35) 0.18 59.09 0.32 
IL-6 21 0.09 (-0.38, 0.56) 0.71 93.20 0.80  19 0.35 (-0.13, 0.83) 0.15 92.73 0.14 
CRP 13 -0.06 (-0.34, 0.23) 0.70 75.59 0.46  11 0.04 (-0.47, 0.55) 0.88 88.01 0.10 
IFNγ 10 -0.60 (-1.41, 0.21) 0.15 95.79 0.15  6 -0.002 (-0.42, 0.42) 0.99 75.07 0.20 
IL-10 10 0.62 (-0.14, 1.38) 0.11 94.19 0.54  8 0.02 (-0.46, 0.50) 0.93 86.11 0.72 
IL-1β 10 0.20 (-0.50, 0.91) 0.57 94.09 0.64  6 0.43 (-0.29, 1.15) 0.24 92.50 0.92 
IL-8 9 -0.21 (-0.69, 0.26) 0.38 90.38 0.12  9 -0.08(-0.47, 0.31) 0.69 80.41 0.15 
IL-4 9 -0.82 (-2.11, 0.48) 0.22 97.91 0.02  7 -0.57 (-1.98, 0.84) 0.42 98.02 0.03
IL-2 8 -0.11 (-1.19, 0.96) 0.84 96.38 0.55  5 -0.14 (-1.01, 0.73) 0.75 92.83 0.09 
IL-12 4 0.28 (-0.05, 0.62) 0.10 0 0.40  3 -0.12 (-0.43, 0.19) 0.45 0 0.93 
GM-CSF 3 0.33 (0.09, 0.56) 0.007 3.58 0.75  3 0.16 (-0.25, 0.54) 0.47 59.66 0.64 
IL-5 3 0.67 (0.44, 0.90) <0.0001 1.55 0.71  3 0.65 (0.02, 1.28) 0.04 80.71 0.35 
MIP-1α 3 0.08 (-1.84, 0.34) 0.56 0 0.12  3 -0.65 (-1.73, 0.43) 0.24 88.78 0.41 
Eotaxin-1 3 0.06 (-0.68, 0.81) 0.87 88.45 0.08  3 0.05 (-0.27, 0.36) 0.77 0 0.99 
 
